3 results
Approved WMORecruiting
Primary:To evaluate the efficacy and safety of anakinra in the treatment of pain in patients with an acute gout attack during 3 days and subsequently assess the effect of anakinra treatment for 21 days in the prevention of recurrent gout attacks.…
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.
Approved WMOCompleted
Primary Safety Objective: To describe the safety profile of 20vPnC